AGC Biologics' Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva's Tetravalent Shigella Vaccine Candidate
Valneva exclusively licensed the vaccine candidate from LimmaTech Biologics AG, which previously worked with AGC Biologics to establish GMP-compliant manufacturing and quality control of the vaccine's complex protein-polysaccharide conjugates for first-in-human studies. The objective of the new partnership with Valneva is to establish phase II supply relying on the ability of AGC Biologics' Heidelberg site to guide complex molecules through clinical stages. Valneva and LimmaTech announced the launch of a Phase 2 infant study in April, and a Phase 2b Human Challenge Study (CHIM) in November 2024.
Shigellosis is the second leading cause of fatal diarrheal disease worldwide, strongly contributing to pediatric morbidity and mortality. It is estimated that up to 165 million infections are due to Shigella, of which 62.3 million occur in children younger than five years. Developing an effective vaccine to prevent this deadly disease is a public health imperative for many areas of the world.
"Our site's unique ability to handle complex molecules and multi-valent assets can help this potentially life-saving program reach its next clinical milestone," said Dieter Kramer, Senior Vice President and General Manager, AGC Biologics Heidelberg. "We appreciate Valneva entrusting our team of experts with this challenge and are honored to contribute to efforts that aim to prevent millions of deadly infections in the future."
AGC Biologics runs multiple cGMP microbial fermentation lines at its Heidelberg facility. The site has produced biologics products for 40 years. It offers developers freedom-to-operate strain development, proven experience with different bacterial and yeast systems, proprietary plasmid DNA (pDNA) and messenger RNA (mRNA) platforms, large-scale tanks for late-phase protein refolding, the ability to take on early-phase and fast track projects, and late-phase and commercial expertise.
To learn more about the microbial system-based biologics, pDNA and mRNA manufacturing site in Heidelberg, visit www.agcbio.com/facilities/heidelberg. For more information on AGC Biologics' global CDMO services across all modalities, go to www.agcbio.com.
About AGC Biologics
AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, to provide friendly and expert services. We provide world-class development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with locations in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba and Yokohama, Japan. We currently employ more than 2,600 Team Members worldwide. AGC Biologics is a part of AGC Inc.'s Life Science Business. The Life Science Business runs 10+ facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit www.agcbio.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Apple is a star (again) as investors hope tariffs don't squeeze markets
Apple is a star (again) as investors hope tariffs don't squeeze markets originally appeared on TheStreet. Stocks had a nifty week last week, especially technology shares. All of the major averages had solid weeks. The Standard & Poor's 500 index rose 2.4%, its best week since June. The Nasdaq Composite Index jumped 3.87%. Its compadre, the Nasdaq-100 Index, added 3.73%. The small-cap Russell 2000 Index moved up 2.38%. And the venerable Dow Jones Industrial Average managed a 1.35% gain. The market's gains came as new tariff rates for goods exported to the United States seemed to settle in at around 15%, with a number of deals not yet finished with a number of countries, including Canada, China and Mexico. What's not clear is the effects tariffs might have on the domestic economy and has added volatility to financial markets. There is a lawsuit now before the U.S. Court of Appeals arguing that the president can not impose tariffs unilaterally. Some stocks had positively gaudy returns. Palantir Technologies () added 21.19% on the week after reporting its second-quarter revenue hit $1 billion, up 48% from a year earlier. It projected $4 billion-plus in revenue for the Networks () jumped 18.4%, and Axon Enterprise () , maker of the Taser and other equipment targeted at law enforcement, rose 13.5%. But there have to be losers, and there were: Eli Lilly () , off nearly 18% Thursday because orforglipron, its GLP-1 weight-loss that can be taken with a pill, didn't perform as well as Novo Nordisk's Wegovy in the latest trial. It was the biggest one-day loss for Lilly in 25 years. The Trade Desk () , an advertising platform that helps advertisers reach audiences across many channels, fell 37%.Apple reminds people they're still around Here we have to note Apple () , a stock many people currently loathe. The iPhone is wonderful, they'll say. So is the Macintosh computer. The graphics are great. But where's the artificial intelligence? Apple doesn't have an AI product to compete directly against Microsoft, Meta Platforms () and Google-parent Alphabet () At the end of July, Apple was down 17.1% for the year. This week, Apple shares were up 13.3%, sixth-best among S&P 500 stocks and the 2024 stock price decline has been cut to 8.4%. Reason: CEO Tim Cook said the company will invest an extra $100 billion on new plants in the United States. In exchange, the Trump Administration agreed to waive tariffs on Apple products made in China and India. Its market cap has risen to $3.4 trillion. Tech led the sectors Among the 11 S&P 500 sectors, technology had the best week, rising 4.27%, followed by Consumer Discretionary at 3.81% and Communications Services. Techs were led by Palantir, Arista Networks, Micron Technology () and Apple. Only three sectors were down on the week: Real Estate, down 0.14%. Health Care, down 0.8%. Energy, down 1%. Crude oil is down 11.7% on the year. The overall S&P 500 Index is up 8.63% and 32% from the bottom after President Trump introduced what's proven to be a first draft of a tariff plan. More Experts Stocks & Markets Podcast: Sectors to Avoid With Jay Woods Trader makes bold call with Boeing stock after defense workers strike Veteran fund manager sends urgent 9-word message on stocks But . . . There's always a catch After the market's decent-to-strong performance this past week, maybe in the back of your mind, you're thinking: Relatively speaking, how does it compare. Nicely, as noted. But the S&P 500 Index, used often as a short hand for the market, hasn't had a record close in (gasp!) nine whole days. Is this the end of the world? Probably not. The index has already seen 15 record closes in 2025, and autumn has not yet arrived. In 2024, in part because of the presidential election, there were 29 new record closes between July 26 and the end of the all, the index generated 57 new closing highs in 2024, according to Howard Silverblatt, Standard & Poor's senior index analyst. The record is still 77 closing highs in 1995. And that was as the Internet Bubble of the late 1990s was just getting started. The timing of new highs quite variable. The S&P 500 hit a closing high of 6,144.15 on Feb. 15. It took 128 days — and the tariff-induced minicrash in April — before the index hit a new record close: 6,173 on June 27. What's ahead for the market? The week ahead includes 621 earnings reports, a goodly number until you remember that last week 1,552 companies reported quarterly results. All will mention tariffs somehow. The reports expected to grab the most attention will be: Dow component Cisco Systems () , due after Wednesday's close. Cisco makes routers and networking equipment. Revenue estimate: $14.5 billion, up 7% from a year ago. Earnings estimate is 91 cents a share, up 4.6%. Chip-equipment maker Applied Materials () , after Thursday's close. The revenue estimate: $7.2 billion, up 5.4% from a year ago. Earnings estimate: $2.35 a share, up 10.9%. Farm-equipment maker Deere & Co. () , before Thursday's open. Revenue estimate: $10.3 billion, down 21.7%. Earnings estimate: $4.60, down 27%. Tapestry () , the owner of Coach leather goods and Kate Spade New York. Revenue estimate: $1.7 billion, up 5.4% from a year ago. Earnings estimate: $1, up 8.7%. Apple is a star (again) as investors hope tariffs don't squeeze markets first appeared on TheStreet on Aug 10, 2025 This story was originally reported by TheStreet on Aug 10, 2025, where it first appeared. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
Allbirds Second Quarter 2025 Earnings: Beats Expectations
Explore Allbirds's Fair Values from the Community and select yours Allbirds (NASDAQ:BIRD) Second Quarter 2025 Results Key Financial Results Revenue: US$39.7m (down 23% from 2Q 2024). Net loss: US$15.5m (loss narrowed by 19% from 2Q 2024). US$1.92 loss per share (improved from US$2.45 loss in 2Q 2024). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period Allbirds Revenues and Earnings Beat Expectations Revenue exceeded analyst estimates by 2.8%. Earnings per share (EPS) also surpassed analyst estimates by 27%. Looking ahead, revenue is forecast to grow 4.2% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Luxury industry in the US. Performance of the American Luxury industry. The company's shares are down 27% from a week ago. Risk Analysis Before we wrap up, we've discovered 3 warning signs for Allbirds (1 is concerning!) that you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
26 minutes ago
- Yahoo
We're Not Very Worried About Odysight.ai's (NASDAQ:ODYS) Cash Burn Rate
Explore Fair Values from the Community and select yours There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse. Given this risk, we thought we'd take a look at whether (NASDAQ:ODYS) shareholders should be worried about its cash burn. In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company spends each year to fund its growth. First, we'll determine its cash runway by comparing its cash burn with its cash reserves. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. When Might Run Out Of Money? A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. As at March 2025, had cash of US$37m and no debt. In the last year, its cash burn was US$9.3m. Therefore, from March 2025 it had 4.0 years of cash runway. A runway of this length affords the company the time and space it needs to develop the business. Depicted below, you can see how its cash holdings have changed over time. Check out our latest analysis for How Well Is Growing? At first glance it's a bit worrying to see that actually boosted its cash burn by 4.4%, year on year. Given that its operating revenue increased 100% in that time, it seems the company has reason to think its expenditure is working well to drive growth. If revenue is maintained once spending on growth decreases, that could well pay off! We think it is growing rather well, upon reflection. Clearly, however, the crucial factor is whether the company will grow its business going forward. So you might want to take a peek at how much the company is expected to grow in the next few years. Can Raise More Cash Easily? We are certainly impressed with the progress has made over the last year, but it is also worth considering how costly it would be if it wanted to raise more cash to fund faster growth. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. Commonly, a business will sell new shares in itself to raise cash and drive growth. By looking at a company's cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another year's cash burn. Since it has a market capitalisation of US$72m, US$9.3m in cash burn equates to about 13% of its market value. Given that situation, it's fair to say the company wouldn't have much trouble raising more cash for growth, but shareholders would be somewhat diluted. How Risky Is Cash Burn Situation? It may already be apparent to you that we're relatively comfortable with the way is burning through its cash. For example, we think its revenue growth suggests that the company is on a good path. While its increasing cash burn wasn't great, the other factors mentioned in this article more than make up for weakness on that measure. After taking into account the various metrics mentioned in this report, we're pretty comfortable with how the company is spending its cash, as it seems on track to meet its needs over the medium term. On another note, we conducted an in-depth investigation of the company, and identified 4 warning signs for (2 can't be ignored!) that you should be aware of before investing here. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies, and this list of stocks growth stocks (according to analyst forecasts) Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
